Predictive value and changes of miR‑34a after concurrent chemoradiotherapy and its association with cognitive function in patients with nasopharyngeal carcinoma

Deng,Weiyu; Lin,Anqi; Yang,Jialin

doi:10.3892/ol.2020.11995

Predictive value and changes of miR‑34a after concurrent chemoradiotherapy and its association with cognitive function in patients with nasopharyngeal carcinoma

Authors:
- Weiyu Deng
- Anqi Lin
- Jialin Yang
View Affiliations

Affiliations: Department of Neurology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China, Department of Pneumology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China, Department of Oncology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China
Published online on: August 20, 2020 https://doi.org/10.3892/ol.2020.11995
Article Number: 134
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study explored the changes and predictive value of miR‑34a in nasopharyngeal carcinoma (NPC) after concurrent chemoradiotherapy (CCRT), and its association with cognitive function. Fifty NPC patients admitted to Shunde Hospital, and another fifty healthy individuals were assigned into treated group and control group, respectively. Patients in the treated group received 3 courses of CCRT. The relative expression of miR‑34a in the two groups was detected, and the cognitive function of patients was assessed. Diagnostic and predictive values of miR‑34a in advanced NPC were analyzed. The expression of miR‑34a in the control group was significantly higher than that in the treated group (t=13.364, P<0.001), with an area under the curve (AUC) of 0.979. The expression of miR‑34a was significantly upregulated after treatment (t=4.559, P<0.001). After treatment, there were 32 complete remission (CR) patients and 18 partial remission (PR) patients. According to efficacy, CR patients were classified as significant group and PR patients as general group. The expression of miR‑34a in the significant group was higher than that in the general group before treatment (t=4.704, P<0.001), with an AUC of 0.852. The Montreal Cognitive Assessment (MoCA) score was significantly decreased after treatment (t=13.042, P<0.001). The expression of miR‑34a was positively correlated with the MoCA score after treatment, that is, MoCA score gradually increased with the upregulation of miR‑34a expression (r=0.379, P=0.006). There is a positive correlation between miR‑34a and cognitive function of patients. Moreover, the expression of miR‑34a can be used as a potential predictor of the efficacy of CCRT in patients with NPC.

View Figures

View References

1	Chua MLK, Wee JTS, Hui EP and Chan ATC: Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17:1509–1520. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y, et al: What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 35:498–505. 2017. View Article : Google Scholar : PubMed/NCBI
5	Chen YZ, Li WF, Wang JY, Wang JM, Ou RY, Zheng XW, Xu YS and Zhao L: Evaluation of time-phase effect on ¹⁸F-FDG PET/CT delineation methods for treatment planning of nasopharyngeal carcinoma. Clin Nucl Med. 41:354–361. 2016. View Article : Google Scholar : PubMed/NCBI
6	Chen Z, Xu L, Xu X and Yuan C: The clinical value of detecting circulating tumour cells in the peripheral blood of nasopharyngeal carcinoma patients. Oncol Lett. 15:6283–6290. 2018.PubMed/NCBI
7	McDowell LJ, Ringash J, Xu W, Chan B, Lu L, Waldron J, Rock K, So N, Huang SH, Giuliani M, et al: A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. Radiother Oncol. 131:179–185. 2019. View Article : Google Scholar : PubMed/NCBI
8	Fasfous AF, Al-Joudi HF, Puente AE and Pérez-García M: Neuropsychological measures in the Arab World: A systematic review. Neuropsychol Rev. 27:158–173. 2017. View Article : Google Scholar : PubMed/NCBI
9	Kozomara A, Birgaoanu M and Griffiths-Jones S: miRBase: From microRNA sequences to function. Nucleic Acids Res. 47D:D155–D162. 2019. View Article : Google Scholar
10	Gao W, Lam JW, Li JZ, Chen SQ, Tsang RK, Chan JY and Wong TS: MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. Oncol Rep. 37:913–920. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wu R, Qiu E, Lin R, Wang J and Lin H: Regulation of nasopharyngeal carcinoma cell proliferation by targeting Notch1 with miR-34a. Int J Clin Exp Pathol. 9:8811–8816. 2016.
12	Xu Y, Chen P, Wang X, Yao J and Zhuang S: miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors. Neurosci Lett. 670:94–104. 2018. View Article : Google Scholar : PubMed/NCBI
13	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
14	Dechaphunkul A, Danchaivijitr P, Jiratrachu R, Dechaphunkul T, Sookthon C, Jiarpinitnun C, Paoin C, Setakornnukul J, Niyomnaitham S, Suktitipat B, et al: 1076P Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT): A multicenter retrospective study. Ann Oncol. 29 (Suppl. 8):viii3842018. View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ai QY, King AD, Mo FKF, Law BKH, Bhatia KS, Ma BB, Poon DMC and Kam MKM: Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. Oral Oncol. 69:74–79. 2017. View Article : Google Scholar : PubMed/NCBI
17	Tan T, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, Ng QS, Tan D, Ong WS, Tan SH, et al: Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 91:952–960. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chan SC, Yeh CH, Yen TC, Ng SH, Chang JT, Lin CY, Yen-Ming T, Fan KH, Huang BS, Hsu CL, et al: Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 45:1297–1308. 2018. View Article : Google Scholar : PubMed/NCBI
19	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:e050052015. View Article : Google Scholar
20	Spence T, Bruce J, Yip KW and Liu FF: MicroRNAs in nasopharyngeal carcinoma. Linchuang Zhongliuxue Zazhi. 5:172016.(In Chinese).
21	Lee KT, Tan JK, Lam AK and Gan SY: MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol. 103:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chen WY, Liu SY, Chang YS, Yin JJ, Yeh HL, Mouhieddine TH, Hadadeh O, Abou-Kheir W and Liu YN: MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 6:441–457. 2015. View Article : Google Scholar : PubMed/NCBI
23	Toraih EA, Ibrahiem AT, Fawzy MS, Hussein MH, Al-Qahtani SAM and Shaalan AAM: MicroRNA-34a: A key regulator in the hallmarks of renal cell carcinoma. Oxid Med Cell Longev. 2017:32693792017. View Article : Google Scholar : PubMed/NCBI
24	Huang G, Du MY, Zhu H, Zhang N, Lu ZW, Qian LX, Zhang W, Tian X, He X and Yin L: miRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells. Biomed Pharmacother. 106:217–224. 2018. View Article : Google Scholar : PubMed/NCBI
25	Long Z, Wang B, Tao D, Huang Y and Tao Z: Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells. Int J Mol Med. 34:1388–1394. 2014. View Article : Google Scholar : PubMed/NCBI
26	Cui M, Xiao H, Li Y, Dong J, Luo D, Li H, Feng G, Wang H and Fan S: Total abdominal irradiation exposure impairs cognitive function involving miR-34a-5p/BDNF axis. Biochim Biophys Acta Mol Basis Dis. 1863:2333–2341. 2017. View Article : Google Scholar : PubMed/NCBI
27	Qiu Y, Guo Z, Han L, Yang Y, Li J, Liu S and Lv X: Network-level dysconnectivity in patients with nasopharyngeal carcinoma (NPC) early post-radiotherapy: Longitudinal resting state fMRI study. Brain Imaging Behav. 12:1279–1289. 2018. View Article : Google Scholar : PubMed/NCBI